Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
Cancer researchers identify the 'switch' that allows intestinal cells to regenerate after injury
Researchers from the University of Colorado Cancer Center have solved a cellular mystery that may lead to better therapies ...
Finanznachrichten3d
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of C avgd28 and C minss and consistent efficacy in ...
Medscape5d
Clinical infectious diseases
Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults.
Medscape6d
The journal of the Royal College of Physicians of Edinburgh
Carriage of multidrug-resistant carbapenemase-producing gram-negative bacteria in patients admitted to NHS Greater Glasgow and Clyde hospitals: Implications for treatment.